Source: International Congress 2014 – ILDs: pathogenesis and clinical features
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Herrmann, L. Wollin (Biberach, Germany). Nintedanib prevents IL-1beta-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors. Eur Respir J 2014; 44: Suppl. 58, 3501

Member's Comments

No comment yet.

Related content which might interest you: Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Nintedanib (BIBF 1120) prevents TGF-beta-induced pro-fibrotic effects in primary human lung myofibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Change of A549 cells characteristics upon stimulation with BALF of patients with interstitial lung diseases Source: International Congress 2014 – ILDs 4 Year: 2014 Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 The role of CCR2+CD4+T cells in lung fibrosis Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis Year: 2014 The effect of pirfenidone with patients with idiopathic pulmonary fibrosis in one university hospital Source: International Congress 2014 – ILDs 4 Year: 2014 Circulating monocytes from interstitial lung disease patients show an activated phenotype Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Measurement of alveolar nitric oxide in IPF patients and in healthy controls Source: International Congress 2014 – ILDs 4 Year: 2014 Effect of nintedanib, pirfenidone, N-acetylcysteine and their combinations on cultured myofibroblast-type cells derived from patients with asbestosis and idiopathic pulmonary fibrosis Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Proportion of idiopathic pulmonary fibrosis among interstitial lung disease in a tertiary care center and its response to treatment Source: International Congress 2014 – ILDs 5 Year: 2014 IL-17+ cells immunoexpression in systemic sclerosis pulmonary fibrosis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Does hypoxemia increases risks in hospitalized patients with diffuse interstitial lung disease? Source: International Congress 2014 – ILDs 6 Year: 2014 Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 Role of dendritic cells in pulmonary fibrosis in mice Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 The efficacy of cyclosporine A in patients with clinicoradiologically diagnosed idiopathic nonspecific interstitial pneumonia Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 The role of detection of myositis specific and associated antibodies in Japanese patient with interstitial lung disease Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014